Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Follicular 5Breast Neoplasms 5Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Lymphoma 4Waldenstrom Macroglobulinemia 3Recurrence 3Pancreatic Neoplasms 3Neoplasms 3Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Burkitt Lymphoma 3Multiple Myeloma 2Lymphoma, Mantle-Cell 2Leukemia 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Brain Neoplasms 2Virus Diseases 1Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Select Advanced Solid Tumors 1Pregnancy Related 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Neuroectodermal Tumors 1

Interventions

Cyclophosphamide 413Methotrexate 250Cytarabine 235Vincristine 192fludarabine phosphate 174Dexamethasone 171fludarabine 147Etoposide 143Peripheral Blood Stem Cell Transplantation 137Filgrastim 132Whole-Body Irradiation 118Mycophenolic Acid 116Busulfan 113Doxorubicin 110Mercaptopurine 109Tacrolimus 107Cyclosporine 95Radiotherapy 93Melphalan 93pegaspargase 90Rituximab 90Prednisone 88Asparaginase 87Daunorubicin 86Granulocyte Colony-Stimulating Factor 76blinatumomab 74Antilymphocyte Serum 71Calcium Dobesilate 69Clofarabine 58Thiotepa 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × Antibodies, Monoclonal × Clear all
NCT00077493 2007-12-28

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

MedImmune LLC

Phase 1 Suspended
95 enrolled
LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡